FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 4 filers reported holding FATE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $238,332 | +136.3% | 63,725 | +34.0% | 0.01% | +100.0% |
| Q3 2023 | $100,840 | -17.3% | 47,566 | +85.7% | 0.00% | 0.0% |
| Q2 2023 | $121,908 | -90.4% | 25,611 | -88.5% | 0.00% | -91.4% |
| Q1 2023 | $1,268,826 | +204.5% | 222,601 | +439.0% | 0.04% | +191.7% |
| Q4 2022 | $416,687 | -40.2% | 41,297 | +32.7% | 0.01% | -47.8% |
| Q3 2022 | $697,000 | -23.7% | 31,111 | -15.6% | 0.02% | -14.8% |
| Q2 2022 | $913,000 | -31.2% | 36,850 | +7.5% | 0.03% | 0.0% |
| Q1 2022 | $1,328,000 | -23.9% | 34,264 | +15.0% | 0.03% | -20.6% |
| Q4 2021 | $1,744,000 | +19.6% | 29,799 | +21.1% | 0.03% | -8.1% |
| Q3 2021 | $1,458,000 | +767.9% | 24,598 | +1106.4% | 0.04% | +516.7% |
| Q1 2021 | $168,000 | -83.4% | 2,039 | -81.7% | 0.01% | -87.2% |
| Q4 2020 | $1,013,000 | +41.1% | 11,142 | -38.0% | 0.05% | +14.6% |
| Q3 2020 | $718,000 | – | 17,960 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |